Covaxin Induces Robust Response, No Serious Adverse Events In Trials

HYDERABAD, 17 DEC 2020:

India’s first indigenous vaccine Covaxin was successful in inducing robust immune response without any serious adverse events during the Phase 1 trials. The trials were conducted on 375 volunteers in July-August, Bharat Biotech said in a research paper. The paper has been uploaded on ‘medRxiv’, a server which carries preprints of research work before it is peer reviewed. The company said a majority of the adverse events observed during the study were mild and were resolved.

“The vaccine was well tolerated in all dose groups with no vaccine-related serious adverse events. Only one serious adverse event was reported, which was found to be unrelated to vaccination,” the paper said about the Phase 1 interim findings.

The research paper said that “after the first vaccination the local and systemic adverse effects events were predominantly mild or moderate in severity and resolved rapidly without any prescribed medication”. According to the paper, the most common adverse event observed during the study was pain at the injection site. “The overall incidence rate of adverse events in this study was 10-20%,” the research paper said.

SOURCE : The Times Of India